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Lecture Objectives
• Apply key findings from the DISCOVER trial to PrEP clinical decision-
making
• Understand the gaps in PrEP research for cisgender women and 
adolescents
• Understand the use of on-demand pre-exposure prophylaxis
• Review Current treatment recs and emerging data on Gonococcal 
and Chlamydial infection
• Discuss diagnostic and management options for non-gonococcal 
urethritis 
Case 1: Switching to Descovy for PrEP?
• 20-year-old man presents for his three-month PrEP visit.  
• He has been seeing a lot of lawsuit ads on TV that Truvada is 
dangerous. 
• He heard that Descovy is now an option.  
• He asks for your opinion about switching to Descovy. 
• How would you advise him?  
PrEP Timeline
• 2012: FDA approved Truvada for HIV 
pre-exposure prophylaxis for adults 
at risk for acquiring HIV
• 2018: Truvada was approved for 
adolescents weighing at least 35 kg 
• 2019: USPSTF made a level A 
recommendation to offer PrEP to 
persons at high risk of HIV 
acquisition
• 2019: FDA approved Gilead’s 
Descovy for PrEP for MSM and TGW, 
not for cis women who engage in 
receptive vaginal sex
CDC, 2018; FDA Briefing Document, 2019; USPSTF, JAMA, 2019.https://www.statnews.com/2020/02/26/newest-prep-pill-hiv-prevention-fuel-progress-or-profits/
Truvada vs. Descovy 
Name Tenofovir Emtricitabine Renal Function Population
Truvada Tenofovir 
disoproxil 
fumarate (TDF)
300 mg
Emtricitabine 
(FTC), 200 mg
Not 
recommended 
if CrCl <60 
mL/min
MSM
TGW
Heterosexual 
PWID 
Descovy Tenofovir 
alafenamide 
(TAF) 
25 mg 
Emtricitabine 
(FTC), 200 mg 
Not 
recommended 
if CrCl <30 
mL/min
MSM
TGW
Prescribing PrEP
Descovy and Truvada: approved for adolescents (>35 kg) 
Truvada is safe in use in pregnancy and breastfeeding 
Gay, Bisexual, and other Men who 
have Sex with Men, and 
Transgender Women
Heterosexual Men and Women People who inject drugs 
• Sexual partner with HIV
• Recent bacterial STD
• High number of sex partners
• History of inconsistent or no 
condom use
• Commercial sex work 
• Sexual partner with HIV 
• Recent bacterial STD
• High number of sex partners
• History of inconsistent or no 
condom use
• Commercial sex work
• Lives in high prevalence area or 
network 
• HIV-positive injecting partner
• Sharing injection equipment
• High risk sexual behavior 
PrEP Labs and Monitoring
Lab Screening and Visits 
Initial visit • HIV test (ideally 4th
gen HIV ag/ab)
• Cr 
• HbsAb/Ag 
• HAV Ab
• HCV Ab
• Pregnancy test
• GC/CT (site-specific)
• Syphilis
• Offer HAV, HBV 
and HPV immunization 
as indicated
Week 1 Call, check if Rx filled, assess adherence and side effects
Month 1 (optional) Assess adherence and side effects
Every 3 months • HIV testing, assess s/sx of acute HIV 
• Repeat pregnancy test for women who may become pregnant 
• STI testing 
At least every 6 months CrCl
At least every 12 months Evaluate need to continue PrEP
Time to steady state levels of TFV-DP: 
Maximum intracellular concentrations of TFV-DP are reached in:
• Blood after 20 days of daily oral dosing
• Rectal tissue after 7 days of daily oral dosing
• Cervico-vaginal tissues at 20 days of daily oral dosing 
CDC 2017
Side effects 
Image credit: Please PrEP Me Navigator Manual
Metabolism of TDF vs. TAF
Image Credit: University of Washington, National HIV Curriculum 
300 mg 
25 mg 
Safety 
Profiles of 
TDF vs. TAF 
(Studies in PLWH)
TDF
• Renal Toxicity: ⇧Prox. Tubule 
Dysfunction, GFR, Cr1-3
• Bone Toxicity: ⇩ BMD2,3
•⬄Weight4, ⬄/⇧ Lipids3
TAF
• More favorable renal and bone profile1-3
• ⇧Weight4
• ⇧ TC, LDL, HDL; ⇔ TC:HDL3
1Gupta et al. AIDS. 2019
2Grant, P and Cotter, A. Curr
Opin HIV AIDS. 2016; 3Wang et 
al. Medicine. 2016; 4Sax et al. 
Clin Infect Dis. 2019
What’s the safety data in people on PrEP? 
Pilkington et al. J Virus Erad. 2018
Grade 1 Cr: 1.1-
1.3x upper limit 
of normal 
Grade 2 Cr: 1.1-
1.8x upper limit 
of normal
DISCOVER: Study Design
• International, randomized, double-blind, active-controlled non-inferiority phase III 
trial
• Prevention services (eg, risk reduction, condoms/lubricant) and adherence 
counseling provided at entry and every 12 wks
• Endpoints of current analysis: HIV incidence and safety, including renal AEs and 
biomarkers, bone fractures, BMD, and metabolic parameters at Wk 96
Ogbuagu. CROI 2020. Abstr 92.
Option for 
open-label FTC/TAF 
up to Wk 144
FTC/TAF 200/25 mg + FTC/TDF Placebo QD
(n = 2694)
FTC/TDF 200/300 mg + FTC/TAF Placebo QD
(n = 2693)
Wk 96
Slide credit: clinicaloptions.com
*Condomless anal sex ≥ 2 times with ≥ 2 unique partners in past 12 wks or rectal gonorrhea, rectal chlamydia, or syphilis in past 24 wks.
HIV and HBV-negative cis-MSM 
and transgender women at 
high risk of HIV* with eGFR 
≥ 60 mL/min; previous 
PrEP use permitted
(N = 5387)
Characteristic FTC/TAF (n = 2694)
FTC/TDF 
(n = 2693)
Median age, yrs (range) 34 (18-76) 34 (18-72)
Race, n (%)
§ White
§ Black
§ Asian
2264 (84)
240 (9)
113 (4)
2247 (84)
234 (9)
120 (5)
Hispanic/Latinx ethnicity, n (%) 635 (24) 683 (25)
Transgender woman, n (%) 45 (2) 29 (1)
HIV risk factors, n (%)
§ Condomless receptive anal sex with ≥ 2 partners in past 12 wks
§ Rectal gonorrhea in past 24 wks
§ Rectal chlamydia in past 24 wks
§ Syphilis in past 24 wks
§ Recreational drug use in past 12 wks
§ Binge drinking (≥ 6 drinks on ≥ 1 occasion; ≥ 1 time/mo)
1616 (62)
274 (10)
342 (13)
230 (9)
1785 (67)
618 (23)
1569 (60)
262 (10)
333 (12)
263 (10)
1786 (67)
599 (22)
Taking FTC/TDF for PrEP at baseline, n (%) 465 (17) 440 (16)
DISCOVER: Baseline Characteristics
Ogbuagu. CROI 2020. Abstr 92. Slide credit: clinicaloptions.com
FTC/TAF is non-inferior to FTC/TDF
• Noninferiority of FTC/TAF vs FTC/TDF for HIV prevention at Wk 96 established
• Upper bound of 95% CI of incidence rate ratio < 1.62
Ogbuagu. CROI 2020. Abstr 92.
HIV Incidence FTC/TAF (n = 2670) FTC/TDF (n = 2655)
Current analysis at Wk 96†
HIV infections, n 8 15
PY of follow-up 5029 5052
HIV incidence/100 PY 0.16 0.30
Incidence rate ratio for FTC/TAF vs FTC/TDF (95% CI) 0.54 (0.23-1.26)
Slide credit: clinicaloptions.com
DISCOVER: Safety Data Through Wk 96
• Both regimens well tolerated with low rates of discontinuation for AEs (1% to 2%)
• FTC/TAF associated with statistically significantly more favorable renal and bone 
safety outcomes vs FTC/TDF
• More favorable eGFRCG changes in overall population, participants aged ≥ 50 yrs, and 
participants with BL CrCl 60 to ≤ 90 mL/min (P < .001 for PrEP regimen comparison in each 
group)
• FTC/TAF: -0.6 mL/min vs. FTC/TDF: -4.1 mL/min 
• More favorable spine and hip BMD changes through Wk 96 (P < .001)
• FTC/TAF: Spine (+1.0%), Hip (+0.6%) vs. FTC/TDF: Spine (-1.4%), Hip (-1.0%) 
Ogbuagu. CROI 2020. Abstr 92.
Slide credit: clinicaloptions.com
DISCOVER: Metabolic Parameters at Wk 96
Ogbuagu. CROI 2020. Abstr 92.
Median Change From BL at Wk 96 FTC/TAF FTC/TDF P Value
Total cholesterol, mg/dL -3 -14 < .001
LDL cholesterol, mg/dL -2 -7 < .001
HDL cholesterol, mg/dL -1 -4 < .001
Triglycerides, mg/dL +3 -4 < .001
Fasting glucose, mg/dL +2 +2 .63
Total cholesterol:HDL ratio +0.1 0 .18
Median body weight, kg +1.7 +0.5 < .001
Slide credit: clinicaloptions.com
§ Wk 96 median BMI: 25.9 with FTC/TAF vs 25.4 with FTC/TDF (P < .001)
̶ BL BMI 25.3 in both arms
Talking Points
Messaging: 
- Descovy is an alternative, non-inferior, safe and effective daily oral PrEP
option for men who have sex with men and transgender women who 
have sex with men.  
- It is not superior nor a “better PrEP.” 
- Can be considered in people who are at risk for renal impairment and 
osteoporosis, older age. 
-4.1 -0.6
+0.6 %-1.0%
-7 -2
+1.7 kg+0.5kg
96 w
The importance of 
including cisgender 
women in research
• Unknown relative importance of serum 
vs. tissue drug levels to provide 
protection against HIV
• Increased risk of HIV acquisition per sex 
act in late pregnancy and postpartum 
• There is no established safety database 
for TAF/FTC in pregnancy 
• Concerns for increased weight gain in 
women on TAF.  
CDC, 2018; UNAIDS. Fact Sheet—Global AIDS Update 2019 Published July 2019.; Thomsen et al. CROI 2018. 
The importance 
of prescribing 
PrEP to 
cisgender 
women 
• Globally, more than 48% of new HIV infections 
are among cis women.
• Cis-gender women make up 1 in 5 new HIV 
infections in the United States, yet fewer than 1 
in 10 are on PrEP.
• Women-controlled option 
Adolescents and PrEP
• 2018, FDA approved TDF/FTC (Truvada) use for adolescents weighing 
>35 kg (77 lbs) for pre-exposure prophylaxis 
• Unique aspects of providing PrEP among adolescents: 
Safety Adherence
Legal Cost
Hosek et al. JAMA Ped. 2017; Hosek et al. J Acquir Immune Defic Syndrome. 2017
✔ Provider may provide service to minor without parental or guardian 
consent
https://www.cdc.gov/hiv/policies/law/states/minors.html
Paying for PrEP
HHS launched this program in December 2019 as 
part of the government’s “End the HIV Epidemic” 
initiative
Case 2: On-Demand PrEP
• 36-year-old man presents for STI screening
• MSM 
• He only has sex once a month, usually planned 
• Is interested in pre-exposure prophylaxis, but does not want to take a 
daily medicaAon
• What do you recommend?
What do you recommend?
a) No PrEP 
b) Daily TDF/FTC
c) On-demand TDF/FTC
d) Daily TAF/FTC
e) On-demand TAF/FTC
On-Demand PrEP (TDF/FTC; Truvada)
• Other terms: “non-daily PrEP,” ”event-driven PrEP,” or “2-1-1 PrEP”
• Off-label use
• Recommended as an alternative to daily PrEP by International Antiviral 
Society-USA and European AIDS Clinical Society for men who have sex with 
men
• Not yet recommended in the 2017/2018 CDC PrEP Guidelines 
Saag et al. JAMA. 2018; https://eacs.sanfordguide.com/art/pre-exposure-prophylaxis; CDC, 2018
How is 2-1-1 done?  
Saberi P. and Scott HM. J Gen Intern Med. 2019
2-1-1
How is 2-1-1 done?  
Saberi P. and Scott HM. J Gen Intern Med. 2019
How is 2-1-1 done?  
Saberi P. and Scott HM. J Gen Intern Med. 2019
IPERGAY Findings 
- RCT in France and Canada of MSM 
and TGW randomized to on-
demand PrEP vs. Placebo
- Median # of pills per month: 15
- 16 new HIV infections
- TDF-FTC: 2 (0.91/100 PY)
- Placebo: 14 (6.60/100 PY
- Relative risk reduction of 86% (95% 
CI, 40-98; P=0.002)
- NNT 17
Molina et al. New Engl J Med. 2015
• Open-label extension of the 
IPERGAY trial
• All par9cipants were offered on-
demand PrEP (n=361)
• Median dura9on of follow-up: 18.4 
months
• Only 2 transgender women (2/361); 
all other par9cipants were cis men
Findings
§ Low incidence of HIV infections
§ On-demand: 0.19/100 PY
§ Placebo: 6.6/100 PY
§ RRR: 97% (CI, 81-100)
§ Similar safety data as randomized 
trial
TDF/FTC PrEP efficacy and Adherence (iPrEx)
Grant RM et al. Lancet Inf. 
Disease. 2014
4 doses and more/week 2-3 doses
wk
What about less frequent sex? 
IPERGAY RCT 2017 Sub-Analyses
Median # of sex acts/month 10 5
Median # of pills taken/month 15 9.5
Person-years # HIV 
infections
HIV incidence rate/100 py (95% CI) P 
Placebo 64.8 6 9.3 (3.4-20.1)
TDF/FTC 68.9 0 0.0 (0.0-5.4) 0.013
Antoni et al. Lancet HIV. 2020
• Post-hoc analyses of 270 participants (134 person-years) who had periods of less 
frequent sex (15 pills or fewer per month) and high PrEP adherence
Who can be offered on-demand PrEP? 
2-1-1 PrEP Daily PrEP
Who can use it? Only studied in MSM 
Small numbers of TGW who have 
sex with men (no frontal sex)
Anyone 
Chronic HBV Can trigger a flare Can be used safely
Planning Need to plan sex at least 2 hours in 
advance
No planning needed
“Forgiveness” Not forgiving of missed doses Forgiving of missed doses during 
the week 
Slide credit: Scott, H. 2019 Ryan White HIV/AIDS Clinical Conference. 
What do you recommend? 
a) No PrEP (No, the patient should be given the option for taking PrEP
given that he is MSM)
b) Daily TDF/FTC (definitely an option)
c) On-demand TDF/FTC (likely effective if able to adhere to regimen)
d) Daily TAF/FTC (Yes, if willing to take daily, on-demand has not been 
studied with TAF/FTC)
e) On-demand TAF/FTC (No, on-demand has not been studied with 
TAF/FTC)
Case 3: 
• 34 yo MSM presents for routine STI screening.
• He has a remote history of chlamydia and has no other prior STI 
history. He is asymptomatic at present and has had 2 new partners 
since his last visit 1 year ago. You order labs which return as follows:
• Syphilis EIA Negative
• HIV Ab/AG Non-reactive
• Urine GC PCR: Negative
• Urine CT PCR: Negative
Case Cont'd
• He messages you 1 week later and states that his most recent partner 
told him he recently tested positive for chlamydia. The patient denies 
any sexual activity since last testing but reports that he has had both 
receptive anal and oral intercourse with this partner. He continues to 
deny any symptoms at present.
• What (if any) additional testing would you order?
Extragenital Chlamydia and Gonorrhea Among Community Venue–Attending Men 
Who Have Sex with Men — Five Cities, United States, 2017
MMWR / April 12, 2019 / 68(14);321–325
• 2371 eligible MSM screened at 
community sites in 5 US cities
• 34% had not been screened in 
prior yr- rates of STI no different
• Take home: Sexually active MSM 
should be screened at least 
annually for chlamydia and 
gonorrhea at all exposed 
anatomic sites; higher risk, every 
3-6 months
GU and Extragenital GC/CT among MSM
Association of HIV Preexposure Prophylaxis With Incidence of Sexually 
Transmitted Infections Among Individuals at High Risk of HIV Infection
JAMA. 2019;321(14):1380-1390. doi:10.1001/jama.2019.2947
• Overall incidence of STI 
91/100person years
• PrEP use was associated with 
increased STI Risk, has not been 
consistently shown across trials
• In this study extragenital 
infections made up 74% of 
Chlamydia and 82% Gonococcal 
infections
Case Cont'd
• You obtain oropharyngeal and rectal NAAT for Chlamydia and 
Gonorrhea. The patient is diagnosed with rectal chlamydia and 
prescribed 1g of azithromycin.
• Three months later, he returned to clinic. He denied having receptive 
anal intercourse in the interim.
• A repeat rectal swab was collected per patient request, which came 
back positive for rectal chlamydia.
• How would you treat him?
Case 3 of persistent rectal chlamydia
A. Retreat with 1g of azithromycin
B. Doxycycline 100 mg BID for 7 days
C. Levofloxacin 500 mg once daily for 7 days
D. Erythromycin 500 mg four times a day for 7 days 
CDC 2015 
Treatment 
Guidelines 
Doxycycline may be more effective at treating 
rectal chlamydia than azithromycin
• Meta-analysis (2014) found much higher cure rates with doxycycline 
than azithromycin for rectal chlamydia: 
• Doxycycline: 99.6%
• Azithromycin: 82.9%
• Efficacy difference: 19.9%, CI: 11.4% to 28.3% 
Kong et al. BMC Infect Dis. 2014
Rectal CT are common in women
• 6% of women who attend STI clinic who were tested for rectal 
chlamydia tested positive
• 68% of women who tested positive for urogenital chlamydia had 
concurrent rectal chlamydia
• 2.2% had rectal only positivity 
• Reported anal intercourse was not associated with rectal chlamydia 
Chandra et al. Sex Transm Infect. 2018
- Prospective multicenter cohort study 
- Doxycycline 100 mg twice daily for 7 days for women initially positive for rectal CT
- Azithromycin 1g single dose in vaginally positive and rectally untested or rectally negative
- Microbiological cure for rectal infections:
- Doxycycline: 95.5% 
- Azithromycin: 78.5% 
- Microbiological cure for vaginal infections:
- Doxycycline: 95.4% 
- Azithromycin: 93.5% 
Doxycycline may be 
more effective than 
azithromycin in 
treating rectal CT in 
women.
Clinical Considerations 
• Azithromycin: 
• 1 dose only
• Easier to do expedited partner treatment 
• May take during pregnancy 
• Effective for genital CT
• Doxycycline:
• 7 day treatment, need to assess for adherence issues
• SE: photosensitivity, GI side effects 
• Contraindicated in pregnancy 
• May be more effective at treating rectal CT
Case of persistent rectal chlamydia 
A. Retreat with 1g of azithromycin 
B. Doxycycline 100 mg BID for 7 days
C. Levofloxacin 500 mg once daily for 7 days
D. Erythromycin 500 mg four times a day for 7 days 
Gonococcal Resistance
Gonorrhea Treatment
• Uncomplicated GC infection of urethra, cervix, pharynx, rectum:
• Preferred:
• Ceftriaxone 250mg IM x 1
• Azithromycin 1g PO x 1
• Alternative: (not for pharyngeal infection)
• Cefixime 400mg PO x 1
• Azithromycin 1g PO x 1
• Cephalosporin Allergy:
• Gemifloxacin 320mg PO x 1 OR Gentamycin 240mg IM x 1 + Azithromycin 2g PO x 1
• Disseminated Infection:
• Ceftriaxone 1g IM/IV q day, Azithromycin 1g- Treat for total of 7 days
Case 4: Non-gonococcal urethritis
• 36 yo man who has sex with women presents with a clear penile 
discharge and dysuria. 
• Empirically treated with azithromycin 1000 mg and ceftriaxone 150 
mg IM in clinic. 
• Urine GC/CT NAAT collected, along with 4th generation HIV screening 
test and treponemal ab.  All tests were negative.  
• Patient returns a week later with persistent symptoms.  
• How would you treat him?  
How would you treat him?  
A) Treat with doxycycline 100 mg BID x 7 days 
B) Treat with moxifloxacin 400 mg PO daily x 7 days 
C) Get more testing
D) Treat with moxifloxacin 400 mg PO daily x 7 days and metronidazole 
2 g PO for one dose
Non-gonococcal urethritis is the most common 
sexually transmitted syndrome in men
• Major causative organisms of urethritis in men:
• C. trachomatis (32.7%) 
• N. gonorrhoeae (24.2%)
• M. genitalium (22.2%)
• T. vaginalis (5.2%)
• Co-infection with C. trachomatis and M. genitalium (5.9%)
• Co-infection with C. trachomatis and N. gonorrhoeae (5.9%)
• Other causative organisms (rare): HSV 1/2, adenovirus, Ureaplasma
urealyticum, anaerobes 
Gaydos et al. Sex Transm Infect. 2009 
Mycoplasma Genitalium
• One of the smallest known free-living organism; smallest genome of 
any species!
• Only pathogenic in the urogenital tract
• Men: discharge, dysuria, urethral stinging/itching, penile tip irritation, 
asymptomatic 
• Women: cervicitis, pelvic inflammatory disease, infertility 
Moi et al. BMC Infectious Diseases. 2015; Workowski et al. MMWR Recomm Rep. 2015
Image credit: https://images.app.goo.gl/7gkShz9d9RVWKXHD8
Diagnostic and Treatment Challenges
• Until 2019, there was no FDA-approved 
assay to detect M. Gent and macrolide 
resistance.  
• FDA approves Hologic’s Aptima M. Gent assay 
(Jan 2019) for vaginal, endocervical, urethral 
and urine
• Increasing resistance to antibiotics
• Single dose azithromycin can induce macrolide 
resistance in M. Gent. 
• Widespread use of azithromycin may explain the 
rise in M. Gent resistance
• Low cure rates with doxycycline (20-40%). 
Preferred first-line for NGU if M gent unknown 
b/c:
• 1) reduces organism load
• 2) does not induce resistance
Moi et al. BMC Infectious Diseases. 2015; Mena et al. Clin Infect Dis. 2009; Schwebke et al. Clin Infect Dis. 2011; Manhart et al. Clin Infect Dis. 2013
Chart Credit: UCSF Grand Rounds, Stephanie Cohen, 2019
https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-test-aid-diagnosis-sexually-transmitted-infection-known-mycoplasma
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NGU: A new treatment approach?
CDC 2015 SFDPH STD Clinic 2019 
• NGU/other syndromes: Doxy 100 mg BID x 7d
• NAAT for GC/CT/Mgen
• Mgen(+): Moxi 400 mg Qd x 7 days
• If moxi fails: Minocycline 100 mg BID x 14 days
Modified: Cohen, S. UCSF Grand Rounds. 
2019; Durukan et al. Clin Infect Dis. 2019
Australian Protocol
• NGU/cervicitis/PID/proctitis/contact to MG: 
doxy 100 mg BID x 7 d
• NAAT for GC/CT/Mgen & macrolide resistance 
mutation (MSM) assay 
• Mgen+/MRM+: Moxi 400 mg qd x 7 days
• Mgen+/MRM-: azithro 1g then 500 mg qd x 3d
Cure rates: Doxy/azithro: 95.4%; Doxi/Moxi: 92%
How would you treat him?  
A) Treat with doxycycline 100 mg BID x 7 days 
B) Treat with moxifloxacin 400 mg PO daily x 7 days 
C) Get more testing, if positive for Mgenà tx with moxifloxacin
D) Treat with moxifloxacin 400 mg PO daily x 7 days and metronidazole 
2 g PO for one dose
Follow-up and Management NGU:
• Treat partners
• If M. gent positive, obtain TOC >3 weeks after treatment
• If GC/CT+, screen for reinfection in 3 months 
• If persistent, eval for possible reinfection, resistance or trichomonas
• May treat pre-emptively with metronidazole 2g orally as a single dose or 
tinidazole 2g orally in a single dose
Workowski et al. MMWR. 2015
CDC STI Screening Recommendations (2015)
Chlamydia Gonorrhea HIV Syphilis Trich HBV HCV**
Cis-Women <25 or risk <25 or risk 13-64yo * Hi Prev/risk Hi Risk Born 1945-65, Hi 
risk
Pregnant <25 or risk <25 or risk All Yes HBsAg Born 1945-
65, Hi risk
MSW *Hi Prev * 13-64 * Hi Risk Born 1945-
65, Hi risk
MSM Q3-12mo Q3-12mo >q12mo* Q3-12 mo Yes Born 1945-
65, Hi risk
HIV+ M Dx, q12mo Dx, q12mo Dx, 12 mo HBsAg, cAb, sAb Dx, q12mo
MSM
HIV+ F Dx, q12mo Dx, q12mo Dx, q12mo Dx, q12mo HBsAg, cAb, sAb Dx
Adolescents F- Yes, M-*hi 
Prev
F-Yes, M-* 13+ *
*= consider in high prevalence settings **= USPSTF recommends screening all adults age 18-79
Thank you! Questions?
